Actualités

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.

AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.

Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.

IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Applying the Dogs of the Dow logic across the entire S&P 500 sounds like a recipe for chasing troubled dividends, but a holding-by-holding look at SDOG reveals a more complicated picture, with two positions that deserve serious scrutiny before you commit capital.

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.

Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.

Merck (MRK) is back in focus for investors after the US Food and Drug Administration approved LIPFENDRA, the first oral PCSK9 inhibitor. This adds a new cardiovascular drug to the company’s portfolio. See our latest analysis for Merck. Merck’s share price is $127.47, with a 30-day share price return of 10.38% and a year-to-date share price return of 19.75%. The 1-year total shareholder return of 56.86% reflects strong momentum alongside frequent product and trial updates. If LIPFENDRA’s...

SCHD's 100-stock structure and rock-bottom fees make it a retiree favorite, but a closer look at its top four holdings reveals one company sitting on a patent cliff that could quietly reshape its income story after 2028.

Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons

GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.

While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors.

Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.

Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.

Many hedge funds have soured on momentum trading, but individual investors have not. Are you ready for the battle royale?

Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Merck (NYSE:MRK) and the rest of the branded pharmaceuticals stocks fared in Q1.

This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.